These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 31618420)

  • 1. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).
    Bashir A; Mathilde Jacobsen S; Mølby Henriksen O; Broholm H; Urup T; Grunnet K; Andrée Larsen V; Møller S; Skjøth-Rasmussen J; Skovgaard Poulsen H; Law I
    Neuro Oncol; 2019 Dec; 21(12):1595-1606. PubMed ID: 31618420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diagnostic accuracy of detecting malignant transformation of low-grade glioma using O-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography: a retrospective study.
    Bashir A; Brennum J; Broholm H; Law I
    J Neurosurg; 2018 Apr; 130(2):451-464. PubMed ID: 29624154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy.
    Ceccon G; Lohmann P; Stoffels G; Judov N; Filss CP; Rapp M; Bauer E; Hamisch C; Ruge MI; Kocher M; Kuchelmeister K; Sellhaus B; Sabel M; Fink GR; Shah NJ; Langen KJ; Galldiks N
    Neuro Oncol; 2017 Feb; 19(2):281-288. PubMed ID: 27471107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential for differentiation of glioma recurrence from radionecrosis using integrated
    Sogani SK; Jena A; Taneja S; Gambhir A; Mishra AK; D'Souza MM; Verma SM; Hazari PP; Negi P; Jadhav GK
    Neurol India; 2017; 65(2):293-301. PubMed ID: 28290392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.
    Kebir S; Fimmers R; Galldiks N; Schäfer N; Mack F; Schaub C; Stuplich M; Niessen M; Tzaridis T; Simon M; Stoffels G; Langen KJ; Scheffler B; Glas M; Herrlinger U
    Clin Cancer Res; 2016 May; 22(9):2190-6. PubMed ID: 26673798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET.
    Werner JM; Weller J; Ceccon G; Schaub C; Tscherpel C; Lohmann P; Bauer EK; Schäfer N; Stoffels G; Baues C; Celik E; Marnitz S; Kabbasch C; Gielen GH; Fink GR; Langen KJ; Herrlinger U; Galldiks N
    Clin Cancer Res; 2021 Jul; 27(13):3704-3713. PubMed ID: 33947699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glioma Recurrence Versus Radiation Necrosis: Single-Session Multiparametric Approach Using Simultaneous O-(2-18F-Fluoroethyl)-L-Tyrosine PET/MRI.
    Jena A; Taneja S; Gambhir A; Mishra AK; Dʼsouza MM; Verma SM; Hazari PP; Negi P; Jhadav GK; Sogani SK
    Clin Nucl Med; 2016 May; 41(5):e228-36. PubMed ID: 26859208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.
    Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD
    J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET.
    Galldiks N; Dunkl V; Stoffels G; Hutterer M; Rapp M; Sabel M; Reifenberger G; Kebir S; Dorn F; Blau T; Herrlinger U; Hau P; Ruge MI; Kocher M; Goldbrunner R; Fink GR; Drzezga A; Schmidt M; Langen KJ
    Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):685-95. PubMed ID: 25411133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suspected recurrence of brain metastases after focused high dose radiotherapy: can [
    Romagna A; Unterrainer M; Schmid-Tannwald C; Brendel M; Tonn JC; Nachbichler SB; Muacevic A; Bartenstein P; Kreth FW; Albert NL
    Radiat Oncol; 2016 Oct; 11(1):139. PubMed ID: 27769279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of gliomas located in the brainstem and spinal cord.
    Tscherpel C; Dunkl V; Ceccon G; Stoffels G; Judov N; Rapp M; Meyer PT; Kops ER; Ermert J; Fink GR; Shah NJ; Langen KJ; Galldiks N
    Neuro Oncol; 2017 May; 19(5):710-718. PubMed ID: 28039366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
    Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K
    J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiparametric Analysis Combining DSC-MR Perfusion and [18F]FET-PET is Superior to a Single Parameter Approach for Differentiation of Progressive Glioma from Radiation Necrosis.
    Panholzer J; Malsiner-Walli G; Grün B; Kalev O; Sonnberger M; Pichler R
    Clin Neuroradiol; 2024 Jun; 34(2):351-360. PubMed ID: 38157019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma.
    Pöpperl G; Goldbrunner R; Gildehaus FJ; Kreth FW; Tanner P; Holtmannspötter M; Tonn JC; Tatsch K
    Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1018-25. PubMed ID: 15877226
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Fleischmann DF; Unterrainer M; Bartenstein P; Belka C; Albert NL; Niyazi M
    J Neurooncol; 2017 Apr; 132(2):277-286. PubMed ID: 28102485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic yield of simultaneous dynamic contrast-enhanced magnetic resonance perfusion measurements and [
    Henriksen OM; Hansen AE; Muhic A; Marner L; Madsen K; Møller S; Hasselbalch B; Lundemann MJ; Scheie D; Skjøth-Rasmussen J; Poulsen HS; Larsen VA; Larsson HBW; Law I
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4677-4691. PubMed ID: 35907033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can Early Postoperative O-(2-
    Buchmann N; Gempt J; Ryang YM; Pyka T; Kirschke JS; Meyer B; Ringel F
    World Neurosurg; 2019 Jan; 121():e467-e474. PubMed ID: 30267942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.
    Piroth MD; Holy R; Pinkawa M; Stoffels G; Kaiser HJ; Galldiks N; Herzog H; Coenen HH; Eble MJ; Langen KJ
    Radiother Oncol; 2011 May; 99(2):218-24. PubMed ID: 21497925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06.
    Barry N; Francis RJ; Ebert MA; Koh ES; Rowshanfarzad P; Hassan GM; Kendrick J; Gan HK; Lee ST; Lau E; Moffat BA; Fitt G; Moore A; Thomas P; Pattison DA; Akhurst T; Alipour R; Thomas EL; Hsiao E; Schembri GP; Lin P; Ly T; Yap J; Kirkwood I; Vallat W; Khan S; Krishna D; Ngai S; Yu C; Beuzeville S; Yeow TC; Bailey D; Cook O; Whitehead A; Dykyj R; Rossi A; Grose A; Scott AM
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3970-3981. PubMed ID: 37563351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of O-(2-(18)F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis.
    Galldiks N; Stoffels G; Filss CP; Piroth MD; Sabel M; Ruge MI; Herzog H; Shah NJ; Fink GR; Coenen HH; Langen KJ
    J Nucl Med; 2012 Sep; 53(9):1367-74. PubMed ID: 22872742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.